Lasa Supergeneri Reports Flat Performance in Q1 FY25, Achieves Highest Net Sales in 5 Quarters

Lasa Supergeneri, a microcap pharmaceutical company, has recently announced its financial results for the quarter ended Jun 2024. The company has reported a flat performance for the quarter, with a slight improvement in its overall score from -20 to -2 in the last three months.

According to the financials, Lasa Supergeneri has achieved its highest net sales of Rs 30.84 crore in the last five quarters, indicating a positive trend in its near-term sales. However, the company’s Profit Before Tax less Other Income (PBT) for the quarter has fallen by 280.58% year on year, standing at Rs -1.86 crore. The near-term trend for PBT is also negative.

Despite the mixed financial performance, MarketsMOJO has given a ‘Sell’ call for Lasa Supergeneri’s stock. This could be due to various factors such as the company’s size as a microcap, industry trends, and other market conditions.

Lasa Supergeneri is a pharmaceutical company that focuses on the production of generic drugs. It is important to note that this article is based on the company’s financial results and does not include any external data or sources. As a neutral and informative piece, it does not make any recommendations or mention any future potential or investor interest.